{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T11:11:36Z","timestamp":1786792296600,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-16750-7","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T10:21:10Z","timestamp":1755944470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of smoking and physical activity on cardiovascular outcomes in type 2 diabetes across steatotic liver disease categories"],"prefix":"10.1038","volume":"15","author":[{"given":"So Hyun","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyuri","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu-na","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myunghwa","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Bin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Man","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu Yeon","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungdo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"key":"16750_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1586\/17474124.2015.965143","volume":"9","author":"A Lonardo","year":"2015","unstructured":"Lonardo, A., Ballestri, S., Targher, G. & Loria, P. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Rev. Gastroenterol. Hepatol. 9, 629\u2013650. https:\/\/doi.org\/10.1586\/17474124.2015.965143 (2015).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"16750_CR2","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/s2468-1253(21)00308-3","volume":"6","author":"A Mantovani","year":"2021","unstructured":"Mantovani, A. et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: An updated systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 6, 903\u2013913. https:\/\/doi.org\/10.1016\/s2468-1253(21)00308-3 (2021).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"16750_CR3","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2024.0042","author":"R Oh","year":"2024","unstructured":"Oh, R. et al. Metabolic dysfunction-associated steatotic liver disease and all-cause and cause-specific mortality. Diabetes Metab. J. https:\/\/doi.org\/10.4093\/dmj.2024.0042 (2024).","journal-title":"Diabetes Metab. J."},{"key":"16750_CR4","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1002\/hep.29546","volume":"67","author":"AM Allen","year":"2018","unstructured":"Allen, A. M. et al. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. Hepatology 67, 1726\u20131736. https:\/\/doi.org\/10.1002\/hep.29546 (2018).","journal-title":"Hepatology"},{"key":"16750_CR5","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1056\/NEJMra0912063","volume":"363","author":"G Targher","year":"2010","unstructured":"Targher, G., Day, C. P. & Bonora, E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl. J. Med. 363, 1341\u20131350. https:\/\/doi.org\/10.1056\/NEJMra0912063 (2010).","journal-title":"N Engl. J. Med."},{"key":"16750_CR6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher, G., Byrne, C. D. & Tilg, H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 69, 1691\u20131705. https:\/\/doi.org\/10.1136\/gutjnl-2020-320622 (2020).","journal-title":"Gut"},{"key":"16750_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000735","author":"S Driessen","year":"2023","unstructured":"Driessen, S. et al. Metabolic dysfunction-associated steatotic liver disease and the heart. Hepatology https:\/\/doi.org\/10.1097\/hep.0000000000000735 (2023).","journal-title":"Hepatology"},{"key":"16750_CR8","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","volume":"70","author":"A Mantovani","year":"2021","unstructured":"Mantovani, A. et al. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut 70, 962\u2013969. https:\/\/doi.org\/10.1136\/gutjnl-2020-322572 (2021).","journal-title":"Gut"},{"key":"16750_CR9","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/meg.0000000000001075","volume":"30","author":"YY Zhou","year":"2018","unstructured":"Zhou, Y. Y. et al. Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: A meta-analysis. Eur. J. Gastroenterol. Hepatol. 30, 631\u2013636. https:\/\/doi.org\/10.1097\/meg.0000000000001075 (2018).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"16750_CR10","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1055\/a-1813-7435","volume":"130","author":"C Liu","year":"2022","unstructured":"Liu, C., Wu, Y., Duan, W. & Xu, W. Cigarette smoking increases the risk of type 2 diabetes mellitus in patients with non-alcoholic fatty liver disease: A population-based cohort study. Exp. Clin. Endocrinol. Diabetes. 130, 793\u2013800. https:\/\/doi.org\/10.1055\/a-1813-7435 (2022).","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"16750_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12933-023-01930-4","volume":"22","author":"SM Jeong","year":"2023","unstructured":"Jeong, S. M. et al. Smoking behavior change and risk of cardiovascular disease incidence and mortality in patients with type 2 diabetes mellitus. Cardiovasc. Diabetol. 22, 193. https:\/\/doi.org\/10.1186\/s12933-023-01930-4 (2023).","journal-title":"Cardiovasc. Diabetol."},{"key":"16750_CR12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.14740\/jocmr5113","volume":"16","author":"K Deshpande","year":"2024","unstructured":"Deshpande, K., Olynyk, J., Ayonrinde, O. & Nosaka, K. Barriers to exercise in patients with metabolic dysfunction-associated steatotic liver disease: A patient survey. J. Clin. Med. Res. 16, 94\u2013105. https:\/\/doi.org\/10.14740\/jocmr5113 (2024).","journal-title":"J. Clin. Med. Res."},{"key":"16750_CR13","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1111\/liv.15947","volume":"44","author":"DJ Cuthbertson","year":"2024","unstructured":"Cuthbertson, D. J. et al. Exercise improves surrogate measures of liver histological response in metabolic dysfunction-associated steatotic liver disease. Liver Int. 44, 2368\u20132381. https:\/\/doi.org\/10.1111\/liv.15947 (2024).","journal-title":"Liver Int."},{"key":"16750_CR14","doi-asserted-by":"publisher","unstructured":"Balogun, O. et al. Effect of combined tobacco use and type 2 diabetes mellitus on prevalent fibrosis in patients with MASLD. Hepatol. Commun. 7 https:\/\/doi.org\/10.1097\/hc9.0000000000000300 (2023).","DOI":"10.1097\/hc9.0000000000000300"},{"key":"16750_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.03.006","author":"ZM Younossi","year":"2024","unstructured":"Younossi, Z. M. et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2024.03.006 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"16750_CR16","doi-asserted-by":"publisher","first-page":"1015919","DOI":"10.3389\/fpubh.2023.1015919","volume":"11","author":"YS Jang","year":"2023","unstructured":"Jang, Y. S., Joo, H. J., Park, Y. S., Park, E. C. & Jang, S. I. Association between smoking cessation and non-alcoholic fatty liver disease using NAFLD liver fat score. Front. Public. Health. 11, 1015919. https:\/\/doi.org\/10.3389\/fpubh.2023.1015919 (2023).","journal-title":"Front. Public. Health"},{"key":"16750_CR17","doi-asserted-by":"publisher","first-page":"205031211774522","DOI":"10.1177\/2050312117745223","volume":"6","author":"A Akhavan Rezayat","year":"2018","unstructured":"Akhavan Rezayat, A. et al. Association between smoking and non-alcoholic fatty liver disease: A systematic review and meta-analysis. SAGE Open. Med. 6, 2050312117745223. https:\/\/doi.org\/10.1177\/2050312117745223 (2018).","journal-title":"SAGE Open. Med."},{"key":"16750_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1055\/s-0040-1701443","volume":"40","author":"F \u00c5berg","year":"2020","unstructured":"\u00c5berg, F. & F\u00e4rkkil\u00e4, M. Drinking and obesity: alcoholic liver disease\/nonalcoholic fatty liver disease interactions. Semin Liver Dis. 40, 154\u2013162. https:\/\/doi.org\/10.1055\/s-0040-1701443 (2020).","journal-title":"Semin Liver Dis."},{"key":"16750_CR19","doi-asserted-by":"publisher","unstructured":"Kim, D., Wijarnpreecha, K., Dennis, B. B., Cholankeril, G. & Ahmed, A. Types of physical activity in nonalcoholic fatty liver disease and All-Cause and cardiovascular mortality. J. Clin. Med. 12 https:\/\/doi.org\/10.3390\/jcm12051923 (2023).","DOI":"10.3390\/jcm12051923"},{"key":"16750_CR20","doi-asserted-by":"publisher","first-page":"102461","DOI":"10.1016\/j.clinre.2024.102461","volume":"48","author":"A Couret","year":"2024","unstructured":"Couret, A. et al. Effect of different modalities of exercise on fatty liver index in patients with metabolic syndrome: The RESOLVE randomized trial. Clin. Res. Hepatol. Gastroenterol. 48, 102461. https:\/\/doi.org\/10.1016\/j.clinre.2024.102461 (2024).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"16750_CR21","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jhep.2024.06.036","volume":"81","author":"D Marti-Aguado","year":"2024","unstructured":"Marti-Aguado, D. et al. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease. J. Hepatol. 81, 930\u2013940. https:\/\/doi.org\/10.1016\/j.jhep.2024.06.036 (2024).","journal-title":"J. Hepatol."},{"key":"16750_CR22","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/gutjnl-2023-331003","volume":"73","author":"HH Lee","year":"2024","unstructured":"Lee, H. H. et al. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut 73, 533\u2013540. https:\/\/doi.org\/10.1136\/gutjnl-2023-331003 (2024).","journal-title":"Gut"},{"key":"16750_CR23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","volume":"155","author":"E Vilar-Gomez","year":"2018","unstructured":"Vilar-Gomez, E. et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: A multi-national cohort study. Gastroenterology 155, 443\u2013457e417. https:\/\/doi.org\/10.1053\/j.gastro.2018.04.034 (2018).","journal-title":"Gastroenterology"},{"key":"16750_CR24","doi-asserted-by":"publisher","first-page":"155800","DOI":"10.1016\/j.metabol.2024.155800","volume":"153","author":"HJ Choe","year":"2024","unstructured":"Choe, H. J., Moon, J. H., Kim, W., Koo, B. K. & Cho, N. H. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up. Metabolism 153, 155800. https:\/\/doi.org\/10.1016\/j.metabol.2024.155800 (2024).","journal-title":"Metabolism"},{"key":"16750_CR25","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1111\/liv.16016","volume":"44","author":"DR Riley","year":"2024","unstructured":"Riley, D. R. et al. The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes. Liver Int. 44, 2538\u20132550. https:\/\/doi.org\/10.1111\/liv.16016 (2024).","journal-title":"Liver Int."},{"key":"16750_CR26","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1136\/bjsports-2016-096197","volume":"52","author":"NA Smart","year":"2018","unstructured":"Smart, N. A., King, N., McFarlane, J. R., Graham, P. L. & Dieberg, G. Effect of exercise training on liver function in adults who are overweight or exhibit fatty liver disease: A systematic review and meta-analysis. Br. J. Sports Med. 52, 834\u2013843. https:\/\/doi.org\/10.1136\/bjsports-2016-096197 (2018).","journal-title":"Br. J. Sports Med."},{"key":"16750_CR27","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1097\/meg.0000000000001135","volume":"30","author":"TT Zou","year":"2018","unstructured":"Zou, T. T. et al. Lifestyle interventions for patients with nonalcoholic fatty liver disease: A network meta-analysis. Eur. J. Gastroenterol. Hepatol. 30, 747\u2013755. https:\/\/doi.org\/10.1097\/meg.0000000000001135 (2018).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"16750_CR28","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1210\/clinem\/dgab795","volume":"107","author":"A Sabag","year":"2022","unstructured":"Sabag, A. et al. The effect of high-intensity interval training vs moderate-intensity continuous training on liver fat: A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 107, 862\u2013881. https:\/\/doi.org\/10.1210\/clinem\/dgab795 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"16750_CR29","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1177\/1559827617726516","volume":"13","author":"A Artese","year":"2019","unstructured":"Artese, A., Stamford, B. A. & Moffatt, R. J. Cigarette smoking: an accessory to the development of insulin resistance. Am. J. Lifestyle Med. 13, 602\u2013605. https:\/\/doi.org\/10.1177\/1559827617726516 (2019).","journal-title":"Am. J. Lifestyle Med."},{"key":"16750_CR30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/s0378-4274(00)00270-8","volume":"118","author":"P Moszczy\u0144ski","year":"2001","unstructured":"Moszczy\u0144ski, P. et al. Immunological findings in cigarette smokers. Toxicol. Lett. 118, 121\u2013127. https:\/\/doi.org\/10.1016\/s0378-4274(00)00270-8 (2001).","journal-title":"Toxicol. Lett."},{"key":"16750_CR31","doi-asserted-by":"publisher","unstructured":"Hejazi, K. & Hackett, D. Effect of exercise on liver function and insulin resistance markers in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. J. Clin. Med. 12. https:\/\/doi.org\/10.3390\/jcm12083011 (2023).","DOI":"10.3390\/jcm12083011"},{"key":"16750_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","volume":"23","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Updated mechanisms of MASLD pathogenesis. Lipids Health Dis. 23, 117. https:\/\/doi.org\/10.1186\/s12944-024-02108-x (2024).","journal-title":"Lipids Health Dis."},{"key":"16750_CR33","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.2174\/138161210792062858","volume":"16","author":"A Gastaldelli","year":"2010","unstructured":"Gastaldelli, A., Folli, F. & Maffei, S. Impact of tobacco smoking on lipid metabolism, body weight and cardiometabolic risk. Curr. Pharm. Des. 16, 2526\u20132530. https:\/\/doi.org\/10.2174\/138161210792062858 (2010).","journal-title":"Curr. Pharm. Des."},{"key":"16750_CR34","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3803\/EnM.2021.1100","volume":"36","author":"Y Lee","year":"2021","unstructured":"Lee, Y. et al. The effects of PPAR agonists on atherosclerosis and nonalcoholic fatty liver disease in ApoE-\/-FXR-\/- mice. Endocrinol. Metab. (Seoul)  36, 1243\u20131253. https:\/\/doi.org\/10.3803\/EnM.2021.1100 (2021).","journal-title":"Endocrinol. Metab. (Seoul)"},{"key":"16750_CR35","doi-asserted-by":"publisher","unstructured":"Cho, E. J. et al. Fatty liver index for predicting nonalcoholic fatty liver disease in an asymptomatic Korean population. Diagnostics (Basel) 11.  https:\/\/doi.org\/10.3390\/diagnostics11122233 (2021).","DOI":"10.3390\/diagnostics11122233"},{"key":"16750_CR36","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","volume":"19","author":"H Lee","year":"2021","unstructured":"Lee, H., Lee, Y. H., Kim, S. U. & Kim, H. C. Metabolic Dysfunction-Associated fatty liver disease and incident cardiovascular disease risk: A nationwide cohort study. Clin. Gastroenterol. Hepatol. 19, 2138\u20132147e2110. https:\/\/doi.org\/10.1016\/j.cgh.2020.12.022 (2021).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"16750_CR37","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/jcma.0000000000001230","volume":"88","author":"XR Liu","year":"2025","unstructured":"Liu, X. R., Yin, S. C., Chen, Y. T. & Lee, M. H. Metabolic dysfunction-associated steatotic liver disease and its associated health risks. J. Chin. Med. Assoc. 88, 343\u2013351. https:\/\/doi.org\/10.1097\/jcma.0000000000001230 (2025).","journal-title":"J. Chin. Med. Assoc."},{"key":"16750_CR38","doi-asserted-by":"publisher","first-page":"102292","DOI":"10.1016\/j.eclinm.2023.102292","volume":"65","author":"JH Moon","year":"2023","unstructured":"Moon, J. H., Jeong, S., Jang, H., Koo, B. K. & Kim, W. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: A nationwide cohort study. EClinicalMedicine 65, 102292. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102292 (2023).","journal-title":"EClinicalMedicine"},{"key":"16750_CR39","doi-asserted-by":"publisher","first-page":"11430","DOI":"10.1038\/s41598-025-94783-8","volume":"15","author":"SH Cho","year":"2025","unstructured":"Cho, S. H. et al. Impact of steatotic liver disease categories on atrial fibrillation in type 2 diabetes: A nationwide study. Sci. Rep. 15, 11430. https:\/\/doi.org\/10.1038\/s41598-025-94783-8 (2025).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16750-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16750-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16750-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T23:03:41Z","timestamp":1756335821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16750-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["16750"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-16750-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures involving human participants were conducted in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The requirement for informed consent was waived because the data were publicly available and de-identified.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"31029"}}